Crossmark

Prognostic models for patients with brain metastases after stereotactic radiosurgery with or without whole brain radiotherapy: a validation study

Crossref DOI link: https://doi.org/10.1007/s11060-018-2958-6

Published Online: 2018-08-21

Published Print: 2018-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Rice, Stephanie R.

Bentzen, Søren M.

Hanna, Andrew

Choi, Enid

Boggs, Drexell H.

Kwok, Young

Hyder, Jalal

Feigenberg, Steven J.

Regine, William F.

Woodworth, Graeme F.

Eisenberg, Howard M.

Yu, Cedric

Biggins, Terri F.

Barnholtz-Sloan, Jill S.

Sperduto, Paul W.

Weltman, Eduardo

Mehta, Minesh P.
License Information

Text and Data Mining valid from 2018-08-21
More Information

Article History

Received: 9 June 2018

Accepted: 24 July 2018

First Online: 21 August 2018

Compliance with ethical standards

:

: MM has served as a consultant for Abbvie, Astra-Zeneca, Celgene, Oncoceutics, Tocagen, and Varian, serves on the DSMB for Monteris and on the BOD of Oncoceutics.